Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial

A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiriyatanakorn, Sirichai, Sungkanuparph, Somnuek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641787/
https://www.ncbi.nlm.nih.gov/pubmed/31341931
http://dx.doi.org/10.1093/ofid/ofz297
_version_ 1783436854530408448
author Wiriyatanakorn, Sirichai
Sungkanuparph, Somnuek
author_facet Wiriyatanakorn, Sirichai
Sungkanuparph, Somnuek
author_sort Wiriyatanakorn, Sirichai
collection PubMed
description A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects.
format Online
Article
Text
id pubmed-6641787
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-66417872019-07-24 Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial Wiriyatanakorn, Sirichai Sungkanuparph, Somnuek Open Forum Infect Dis Brief Report A randomized controlled noninferiority trial was conducted in HIV-infected patients receiving tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) with virological suppression in a resource-limited setting. Switching to TDF/FTC/rilpivirine was noninferior to continuing TDF/FTC/EFV in terms of maintaining compete viral suppression at 24 weeks and provided better lipid profiles and fewer central nervous system adverse effects. Oxford University Press 2019-06-26 /pmc/articles/PMC6641787/ /pubmed/31341931 http://dx.doi.org/10.1093/ofid/ofz297 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Wiriyatanakorn, Sirichai
Sungkanuparph, Somnuek
Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title_full Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title_fullStr Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title_full_unstemmed Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title_short Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
title_sort switching tenofovir/emtricitabine/efavirenz (tdf/ftc/efv) to tdf/ftc/rilpivirine vs continuing tdf/ftc/efv in hiv-infected patients with virological suppression: a randomized controlled trial
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641787/
https://www.ncbi.nlm.nih.gov/pubmed/31341931
http://dx.doi.org/10.1093/ofid/ofz297
work_keys_str_mv AT wiriyatanakornsirichai switchingtenofoviremtricitabineefavirenztdfftcefvtotdfftcrilpivirinevscontinuingtdfftcefvinhivinfectedpatientswithvirologicalsuppressionarandomizedcontrolledtrial
AT sungkanuparphsomnuek switchingtenofoviremtricitabineefavirenztdfftcefvtotdfftcrilpivirinevscontinuingtdfftcefvinhivinfectedpatientswithvirologicalsuppressionarandomizedcontrolledtrial

Ejemplares similares